about
Pazopanib for the treatment of metastatic renal cell carcinomaPhase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.Pazopanib: therapeutic developments.Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.Pazopanib for the treatment of renal cancer.Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.Pazopanib.Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.[Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].Gateways to clinical trialsGateways to clinical trialsTyrosine kinase inhibitors for metastatic renal cell carcinomaGateways to clinical trialsGateways to Clinical TrialsGateways to clinical trialsGateways to clinical trialsGateways to clinical trials[Pharmacological sheet: pazopanib (Votrient), oral administration]
P921
Q28260084-A9A68F5C-5B33-4E34-A781-A173428701BBQ33401692-DE6EA5E5-B1F1-4809-8759-4B9D50D3E026Q33429798-64EF7310-61A5-4E01-813E-C2688956B98EQ37642770-82821D3A-8750-49E2-9789-4C5F16974BF9Q37734709-87D57160-96DF-44B4-AB94-C4EC98D4F798Q37862259-E1051464-B277-4618-A5E9-A7C457FD2545Q43147457-02F46462-4093-41B4-89BC-27C1E1DB91AFQ43204474-3E72CC20-C764-435E-ADA0-3974649A254FQ46019552-CE51450A-C4C3-44D0-BBD4-886FE0462C4EQ54483146-97C6738F-15BA-4014-87AB-1B65D097E2FAQ57220419-71FA5496-BCF5-466F-B26E-43E7E642B33FQ80052549-B22A58CA-8965-4DAB-A7EA-66A68A4599ABQ82461177-F24DA219-A3E5-4D43-B4C7-EF30EF50917AQ83171857-44A7D2B3-CFE1-41F6-8776-1C62D246B2B7Q83379820-41AA640D-6A20-43A4-801A-89120B77FDBAQ84039655-F018CDD3-DF0E-45D3-B8C2-E159B3216FE3Q84617438-DF5B043A-30E5-427B-A742-3298C9B182D4Q84993285-2CA3BB66-1B56-4C57-90F9-7AB309EC3964Q85087051-35229975-8A95-4E3E-9394-03778F50C035
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
pazopanib hydrochloride
@en
type
label
pazopanib hydrochloride
@en
prefLabel
pazopanib hydrochloride
@en
P592
P661
P662
P683
P231
635702-64-6
P232
P233
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
P234
1S/C21H23N7O2S.ClH/c1-13-5-6-1 ...... 3,(H2,22,29,30)(H,23,24,25);1H
P235
MQHIQUBXFFAOMK-UHFFFAOYSA-N
P2566
100.115.956
P274
C₂₁H₂₄ClN₇O₂S
P3117
DTXSID70212956
P3345
P592
CHEMBL1201733
P652
33Y9ANM545